– The PULSAR trial achieved its primary endpoint: a statistically significant reduction in pulmonary vascular resistance – – The trial also achieved statistically significant improvements in the key secondary endpoint of six-minute walk distance (6MWD) and other secondary endpoints, including amino-terminal brain natriuretic propeptide (NT-proBNP), and World Health Organization (WHO) […]